Gene Editing

Gene Editing is a thematic segment focused on technologies that precisely modify DNA to treat disease, engineer cells, and enhance biological systems. Core tracks include CRISPR and next‑gen editors (base/prime), in vivo and ex vivo therapeutics, delivery platforms (AAV/LNP), cell and gene therapy pipelines, enabling reagents and tools, and agricultural and synthetic biology applications.The sector's total market cap is 127.22 billion USD, with a 24h change of +0.34%. Among 3 constituents, 2 are up (66.67%) and 1 are down (33.33%). The top gainer is CRISPR Therapeutics AG (CRSP), with a 24h increase of +0.49%.Leaders drove a mild, selective advance as flows favored quality names. Near term, buy strength on pullbacks; medium term, prioritize late‑stage catalysts while balancing regulatory and financing risks.